Cargando…
False or Misleading Claims in Online Direct-to-Consumer Ketamine Advertising in Maryland
This cross-sectional study evaluates the prevalence of false or misleading information in online direct-to-consumer advertising for off-label and unapproved ketamine in Maryland.
Autores principales: | Crane, Matthew A., DiStefano, Michael J., Moore, Thomas J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630893/ https://www.ncbi.nlm.nih.gov/pubmed/37934500 http://dx.doi.org/10.1001/jamanetworkopen.2023.42210 |
Ejemplares similares
-
Consumer Advertising Can Be Misleading
por: Rickels, Karl
Publicado: (2006) -
Businesses marketing purported stem cell treatments and exosome therapies for COVID-19: An analysis of direct-to-consumer online advertising claims
por: Turner, Leigh, et al.
Publicado: (2023) -
IQOS labelling will mislead consumers
por: McKelvey, Karma, et al.
Publicado: (2018) -
Oral nicotine marketing claims in direct-mail advertising
por: Czaplicki, Lauren, et al.
Publicado: (2022) -
Trade Agreements and Direct-to-Consumer Advertising of Pharmaceuticals
por: Gleeson, Deborah, et al.
Publicado: (2017)